Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting

Perfusion

Volumn 24, Issue 4, 2009, Pages 271-276

  Kurban, Sevil ^a   Mehmetoglu, Idris ^a   Ege, Erdal ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

atorvastatin; coronary artery bypass grafting; paraoxonase; total antioxidant status; total oxidant status

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ATOR; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; CARBOXYLESTERASE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZING AGENT; PYRROLE DERIVATIVE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ASSISTED VENTILATION; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITALIZATION; HUMAN; HYDROLYSIS KINETICS; HYPERLIPIDEMIA; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; MALE; MORBIDITY; OXIDATIVE STRESS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION; AGED; BLOOD; CORONARY ARTERY DISEASE; ENZYMOLOGY; MIDDLE AGED; PREOPERATIVE CARE;

AGED; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; PREOPERATIVE CARE; PYRROLES;

EID: 75649113447     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659109350240     Document Type: Article

References (26)

1. Werba JP, Tremoli E., Massironi P., et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 2003 ; 76: 2132-2140.
2. Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Drugs Today (Barc) 2004 ; 40: 975-990.
3. Bolayirli IM, Aslan M., Balci H., et al. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007 ; 81: 121-127.
4. Dereli Y., Ege E., Kurban S., et al. Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting. J Int Med Res 2008 ; 36: 1248-1254.
5. Aviram M., Rosenblat M., Bisgaier CL, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998 ; 138: 271-280.
6. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med. 2004 ; 37: 1304-1316.
7. Aviram M., Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005 ; 16: 393-399.
8. Mackness B., Davies GK, Turkie W., et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001 ; 21: 1451-1457.
9. Serdar Z., Aslan K., Dirican M., et al. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006 ; 39: 794-803.
10. Granér M., James RW, Kahri J., et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006 ; 47: 2429-2435. (Pubitemid 43866362)
11. Sardo MA, Campo S., Bonaiuto M., et al. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin 2005 ; 21: 777-784.
12. Harangi M., Seres I., Varga Z., et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 2004 ; 60: 685-691.
13. Paragh G., Törocsik D., Seres I., et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 2004 ; 20: 1321-1327.
14. Deblier I., Sadowska AM, Janssens A., et al. Markers of inflammation and oxidative stress in patients undergoing CABG with CPB with and without ventilation of the lungs: a pilot study. Interact Cardiovasc Thorac Surg 2006 ; 5: 387-391.
15. Pechan I., Olejarova I., Danova K., et al. Antioxidant status of patients after on-pump and off-pump coronary artery bypass grafting. Bratisl Lek Listy 2004 ; 105: 45-50.
16. Eckerson HW, Wyte CM, La Du BN The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983 ; 35: 1126-1138.
17. Haagen L., Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992 ; 30: 391-395.
18. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004 ; 37: 277-285.
19. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005 ; 38: 1103-1111.
20. Romić Z., Mayer L., Sutlić Z., et al. Paraoxonase activity and concentration of indicators of lipids status in the serum of cardiac patients. Coll Antropol 2003 ; 27: 93-100.
21. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999 ; 26: 892-904.
22. Kotur-Stevuljevic J., Spasic S., Jelic-Ivanovic Z., et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 2008 ; 41: 1067-1073.
23. Nguyen SD, Sok DE Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 2003 ; 37: 1319-1330.
24. Rozenberg O., Aviram M. S-Glutathionylation regulates HDLassociated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006 ; 351: 492-498.
25. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995 ; 96: 2882-2891.
26. Bergheanu SC, Van Tol A., Dallinga-Thie GM, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007 ; 23: 2235-2240.